Immunomodulatory

Phase 2Small molecule

AAljazeera Hospital

Immunomodulatory is one of 12 small molecule programs targeting Thyroiditis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ThyroiditisActive, not recruiting

ThyroiditisPhase 2

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Thyroiditis

#DrugCompanyPhaseTrials

Keytruda

Glucophage

Thyroxine

WWashington University School of Medicine

Phase 2

1 4

Plaquenil

Alnylam Pharmaceuticals

Preclinical

2 5

Immunomodulatory

AAljazeera Hospital

Phase 2

1 6

Treatment as Usual

AAB Biotics, SA

Preclinical

1 7

Selenium

SSWOG Cancer Research Network

Preclinical

1 8

Potassium Iodide

DDawnrays Pharmaceutical (Holdings) Limited

Preclinical

—9

Methimazole Pill

FFirst Affiliated Hospital of Harbin Medical University

Preclinical

1 10

L-Selenomethionine

SSWOG Cancer Research Network

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Thyroiditis1 trial

The Role of Immunomodulatory Treatment in Success of ICSI in Patients With Autoimmune Thyroiditis

Completed·—·Phase 2·NCT03289403·194 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Immunomodulatory. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Immunomodulatory compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Immunomodulatory. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aljazeera Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAljazeera Hospital

Immunomodulatory

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Thyroiditis1 trial

References

Drug Info

Quick Facts

Related News